Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Assets (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Other Non-Current Assets for 10 consecutive years, with $31000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Assets changed N/A to $31000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $31000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $8.7 million for FY2024, 77.87% down from the prior year.
  • Other Non-Current Assets hit $31000.0 in Q3 2025 for Seres Therapeutics, down from $8.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $41.5 million in Q2 2024 to a low of $31000.0 in Q1 2025.
  • Historically, Other Non-Current Assets has averaged $10.1 million across 5 years, with a median of $8.2 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 1819.8% in 2022 and later tumbled 99.63% in 2025.
  • Year by year, Other Non-Current Assets stood at $5.2 million in 2021, then soared by 57.74% to $8.2 million in 2022, then surged by 378.52% to $39.2 million in 2023, then tumbled by 77.87% to $8.7 million in 2024, then tumbled by 99.64% to $31000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for MCRB at $31000.0 in Q3 2025, $8.7 million in Q2 2025, and $31000.0 in Q1 2025.